Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.
暂无分享,去创建一个
[1] J. Armand,et al. Pharmacological and preclinical toxicological studies of 1,2-diaminocyclohexane(isocitrato)platinum(II). , 1984, Cancer research.
[2] F. Lévi,et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. , 1994, Journal of the National Cancer Institute.
[3] N. Mulder,et al. Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex. , 1993, European journal of cancer.
[4] J. Kavanagh,et al. Carboplatin in refractory epithelial ovarian cancer. , 1989, Seminars in oncology.
[5] B. Issell,et al. New platinum complexes in clinical trials. , 1983, Cancer treatment reviews.
[6] S. Fosså,et al. Lobaplatin in advanced urothelial tract tumors , 1997 .
[7] P. O'dwyer,et al. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule. , 1992, Cancer research.
[8] L. Pendyala,et al. Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP). , 1983, Cancer treatment reports.
[9] W. Hong,et al. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] E. Douple,et al. Platinum Coordination Complexes in Cancer Chemotherapy , 2011, Developments in Oncology.
[11] K. Eguchi,et al. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. , 1991, Cancer research.
[12] L. Kèlland,et al. Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin. , 1995, European journal of cancer.
[13] E Wiltshaw,et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Houin,et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. , 1995, Journal of the National Cancer Institute.
[15] P. Fumoleau,et al. Preliminary phase II trial of oxaliplatin (L-OHP) in malignant astrocytomas , 1993 .
[16] E. Reed,et al. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin. , 1993, Cancer research.
[17] H. Fiebig. Phase I and II Studies with Lobaplatin , 1996 .
[18] D. Crowther,et al. Original article: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma , 1990 .
[19] A. Cats,et al. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. , 1995, British Journal of Cancer.
[20] Hill Jm,et al. Organo-platinum complexes as antitumor agents (review). , 1982 .
[21] N. Mulder,et al. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. , 1993, British Journal of Cancer.
[22] P. Langenberg,et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] G. Mathé,et al. CLINICAL RESULTS WITH CISPLATIN ANALOGS , 1980 .
[24] Barnett Rosenberg,et al. Charles F. Kettring prize. Fundamental studies with cisplatin , 1985 .
[25] D. Crowther,et al. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] B. Carr,et al. cis-Platinum (II) Diamminedichloride , 1974 .
[27] M. Slavik,et al. Phase I clinical trials. , 1977, National Cancer Institute monograph.
[28] J. Gietema,et al. A PHASE-I STUDY OF IOBAPLATIN (D-19466) ADMINISTERED BY 72H CONTINUOUS INFUSION , 1993 .
[29] T. A. Connors,et al. Platinum Coordination Complexes in Cancer Chemotherapy , 1974, Recent Results in Cancer Research.
[30] F. Cavalli,et al. Phase II study of iproplatin in advanced ovarian carcinoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Crooke,et al. Cisplatin : current status and new developments , 1980 .
[32] G. Mathé,et al. Antitumor activity of l-OHP in mice. , 1985, Cancer letters.
[33] D. M. Watkins,et al. Anti-tumour platinum complexes : relationships between chemical properties and activity , 1978 .
[34] J. Burchenal,et al. Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia. , 1977, Cancer research.
[35] A. Howell,et al. Activity of JM9 in advanced ovarian cancer: a phase I-II trial. , 1985, Cancer treatment reports.
[36] S. Carter,et al. Carboplatin: the clinical spectrum to date. , 1985, Cancer treatment reviews.
[37] W. Rose. Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models , 1997, Cancer Chemotherapy and Pharmacology.
[38] J. Burchenal,et al. Phase I and Early Phase II Trials of 4′Carboxyphthalato (1,2 Diaminocyclohexane) Platinum (II) , 1984 .
[39] J. Holland,et al. Diamminodichloroplatinum in the chemotherapy of testicular tumors. , 1974, The Journal of urology.
[40] W. Rose,et al. Preclinical antitumor and toxicologic profile of carboplatin. , 1985, Cancer treatment reviews.
[41] I. Judson,et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] R. Livingston. Small cell carcinoma of the lung. , 1980, Blood.
[43] L. Einhorn,et al. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. , 1977, Annals of internal medicine.
[44] M. Zucchetti,et al. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] R. Perez-soler,et al. Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). , 1990, Cancer research.
[46] M. Piccart,et al. Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] K. Harrap. Preclinical studies identifying carboplatin as a viable cisplatin alternative. , 1985, Cancer treatment reviews.
[48] D. V. Von Hoff,et al. cis-Diamminedichloroplatinum(II): a metal complex with significant anticancer activity. , 1979, Advances in pharmacology and chemotherapy.
[49] S. Garattini. Advances in pharmacology and chemotherapy , 1969 .
[50] Tomoko Matsumoto,et al. Toxicological and Tumoricidal Evaluations of a New Platinum Complex, (–)‐(R)‐2‐Aminomethy lpyrrolidine (1,1‐cyclobutanedicarboxylato) platinum (II) Monohydrate, in Rats , 1991, Japanese journal of cancer research : Gann.
[51] P. Chollet,et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[52] BARNETT ROSENBERG,et al. Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.
[53] G. M. Findlay. Recent advances in chemotherapy , 1939 .
[54] F. Boccardo,et al. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. , 1995, Anticancer research.
[55] H. Earl,et al. A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] M. Wolpert-DeFilippes. ANTITUMOR ACTIVITY OF CISPLATIN ANALOGS , 1980 .
[57] L. Kèlland,et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. , 1993, Cancer research.
[58] F. Lévi,et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. , 1990, Journal of the National Cancer Institute.
[59] D. Dunlop,et al. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[60] K. Harrap. Initiatives with platinum- and quinazoline-based antitumor molecules--Fourteenth Bruce F. Cain Memorial Award Lecture. , 1995, Cancer research.
[61] M. Rozencweig,et al. Carboplatin: current status and future prospects. , 1988, Cancer treatment reviews.
[62] N. Newman,et al. Phase II Study of Iproplatin (CHIP) in Previously Treated Small‐Cell Lung Cancer , 1989, American journal of clinical oncology.
[63] D. Alberts,et al. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study. , 1991, European journal of cancer.